Company overview
CN Bio is a world-leading provider of organ-on-chip microphysiological systems (MPS) that accelerate drug discovery and development. Their PhysioMimix platform enables pharmaceutical companies to recreate human organs and tissues in vitro for drug efficacy, safety, and ADME profiling before clinical trials. By offering both single and multi-organ capabilities with reliable microfluidics and computational modeling tools, CN Bio reduces development time and costs while improving predictive accuracy compared to traditional cell culture and animal models.
Organ-on-Chip Drug Discovery Solutions is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services partner serving United States & Americas. Core focus areas include organ-on-chip, microphysiological systems, drug discovery, adme profiling, physiomimix.
Industry categories: CRO & Clinical Services. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Organ-on-Chip Drug Discovery Solutions include Cro — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://cn-bio.com
- Categories
- CRO & Clinical Services
- Markets served
- United States & Americas
- Keywords
- organ-on-chip, microphysiological systems, drug discovery, adme profiling, physiomimix
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are organ-on-chip systems and how do they benefit drug discovery?
- Organ-on-chip systems are microphysiological systems that recreate three-dimensional human organs and tissues in the laboratory. They provide more accurate prediction of drug efficacy and safety than traditional cell culture, while reducing the need for expensive animal and human clinical trials, thereby accelerating time-to-market and lowering development costs.
- What specific applications does CN Bio's PhysioMimix platform support?
- CN Bio's PhysioMimix platform supports drug efficacy assessment, safety profiling, ADME (Absorption, Distribution, Metabolism, and Excretion) analysis, disease modeling, and multi-organ integration. The platform includes organ-specific consumables and can recreate both healthy physiology and complex human disorders for comprehensive drug evaluation.
- Does CN Bio offer contract research services?
- Yes, CN Bio provides Contract Research Services (CRS) that include ADME profiling enhanced with computational modeling capabilities through their PhysioMimix tools, enabling accelerated bioavailability profiling and drug metabolism assessment for pharmaceutical clients.
Related editorial coverage
- Drug Discovery USA 2026: What to Expect
- Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy
- Verge Rebrands AI Drug Discovery After Trial Setback
- Streamlined R&D at Novo Nordisk: Insights from Research Chief Petersen
- BBSW AI Solution Event: Daily Roundup
- BBSW AI Solution Event: Biotech Innovation in US
Explore lab tools and QA/QC resources for R&D teams.
